Flash is not installed.

Get Adobe Flash player

www.dendreon.com
Separator
Activation Progress

ACTIVATION is a new resource designed to provide up-to-date information on Dendreon's step-by-step journey…Read More

Separator

Register for Updates

Separator

Virtual Manufacturing Tour Virtual Manufacturing Tour

Separator

Separator

Separator


View by Date View by Author

Separator

Welcome to ACTIVATION

Posted by: , Seattle, Washington

Dendreon

Welcome to ACTIVATION, a new feature on Dendreon.com. As a company centered on putting patients first, we’ve created this site to give you an inside look at what’s happening behind the scenes as we prepare for what we hope will be the approval of the first active cellular immunotherapy (ACI) product, sipuleucel-T, for men with advanced prostate cancer. …Read More


Separator

Expanding Our Facilities

Posted by: , Vice President of Facilities and Engineering

The Dendreon team has been working tirelessly over recent months on the build out of our New Jersey facility in order to expand capacity and provide sipuleucel-T to patients as quickly as possible. …Read More


Separator

Introduction to Intellivenge™

Posted by: , Chief Information Officer

One of the most exciting aspects of sipuleucel-T is that – if approved by the FDA – it will be the first in a new class of cancer treatments and unlike any other therapy available for advanced prostate cancer patients. What makes sipuleucel-T so unique is …Read More


Separator

Selecting Our New Manufacturing Facility Locations

Posted by: , Senior Director, Supply Operations

In 2010, it is estimated that over three-quarters of a million men will have prostate cancer [Mattson Jack Group, 2009 Cancer Metric Database] and will be seeking treatment. The green dots on the visual below depict where these patients live. …Read More


Separator

Milestone Momentum: BLA Submission

Posted by: , President and Chief Executive Officer

One of Dendreon’s crowning achievements was the positive results of the Phase 3 IMPACT study in April 2009.  This pivotal study was the largest of its kind conducted in men with metastatic castrate-resistant prostate cancer, and we were very encouraged by the outcome. Our next accomplishment was compiling these data into our Biologics License Application (BLA) …Read More


Separator

Atlanta Ribbon-Cutting

Posted by: , Senior Director of Government Affairs

Yesterday, Dendreon broke ground in Atlanta. I attended the ribbon-cutting ceremony at the newest Dendreon manufacturing facility in Union City, Georgia, part of Atlanta’s new Opportunity Zone. The 160,000 square-foot facility is located at the Majestic Airport Center in South Fulton County, and September 30th marked the first “official” day of construction. …Read More


Separator

Developing the First ACI

Posted by: , Senior Vice President, Operations

Dendreon’s work extends far beyond our home base in Seattle, Washington. While our Seattle-based team has been working hard on the pending BLA amendment, things have also been ramping up at our commercial manufacturing facility in Morris Plains, New Jersey. …Read More


Separator

Introduction to ACIs

Posted by: , Ph.D., Chief Scientific Officer

For more than a decade, I’ve had the exciting opportunity to work on the clinical development of sipuleucel-T, which may be the first FDA approved active cellular immunotherapy (ACI) product. ACI is a novel approach to cancer treatment that harnesses the power of a patient’s own immune system to attack cancer cells. …Read More




Separator